The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
复制标题
DOI：
10.1007/s00535-013-0872-4
复制
发表时间：
2014-01
影响因子：
6.3
通讯作者：
Hibi, Toshifumi
中科院分区：
文献类型：
--
作者：
Hisamatsu, Tadakazu;Ueno, Fumiaki;Matsumoto, Takayuki;Kobayashi, Kiyonori;Koganei, Kazutaka;Kunisaki, Reiko;Hirai, Fumihito;Nagahori, Masakazu;Matsushita, Mitsunobu;Kobayashi, Kenji;Kishimoto, Mitsumasa;Takeno, Mitsuhiro;Tanaka, Masanori;Inoue, Nagamu;Hibi, Toshifumi
关于肠道behet病（BD）管理的临床证据缺乏，肠道病变是一个不良的预后因素。2007年，日本制定了肠双相障碍诊断和治疗共识声明。最近，抗肿瘤坏死因子(TNF)α单克隆抗体（mab）和英夫利昔单抗（IFX）的疗效被报道，阿达木单抗（ADA）在日本被批准用于肠道BD。这项研究更新了基于共识的肠道双相障碍的诊断和治疗实践指南，重点关注抗tnf α单克隆抗体的适应症。一个由日本胃肠病学和风湿病学专家组成的专家小组参与了研究。临床陈述的评级是从文献中提取的，一个专业的小组调查，并通过一个专家小组讨论，对临床陈述进行了9分制的评级。在第一轮评级之后，一个小组成员会议讨论了存在分歧的领域，并澄清了不确定的领域。小组成员会议结束后对临床陈述表进行修订，并进行第二轮评分。选取了15篇相关文章。基于第一版共识声明，改进了抗tnf α单克隆抗体使用适应症的临床声明。经过两轮修改的德尔菲方法，第二版共识声明最终确定。除了第一版的标准治疗外，抗tnf α单克隆抗体（ADA和IFX）应被视为肠道BD的标准治疗。秋水仙碱、沙利度胺、其他药物治疗、内镜治疗和白细胞清除被视为实验治疗。
Clinical evidence regarding intestinal Behçet’s disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
登录
查看更多内容
影响因子：
3.4
作者：
Ju, Ji Hyeon;Kwok, Seung-Ki;Park, Sung-Hwan
通讯作者：
Park, Sung-Hwan
影响因子：
1.2
作者：
Maruyama, Yuriko;Hisamatsu, Tadakazu;Hibi, Toshifumi
通讯作者：
Hibi, Toshifumi
影响因子：
24.5
作者：
Travis, SPL;Czajkowski, M;Bell, AL
通讯作者：
Bell, AL
DOI：
10.1097/mpg.0b013e3181346b60
发表时间：
2008-02-01
影响因子：
2.9
作者：
Ugras, Meltem;Ertem, Deniz;Pehlivanoglu, Ender
通讯作者：
Pehlivanoglu, Ender
影响因子：
29.4
作者：
Hassard, PV;Binder, SW;Vasiliauskas, EA
通讯作者：
Vasiliauskas, EA